Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved March 5, 2020 - NASDAQ Companies 0 Outlook Therapeutics intends to market ONS-5010 as LYTENAVA™Bay Street News » View More News for March 05, 2020